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Abstract
Background: Failure to take medicines for diabetes as prescribed contributes to poor outcomes from the
condition. Mobile phones are ubiquitous and short message service (SMS) texts have shown promise as a low-cost
intervention. We tested the effectiveness of SMS-text messaging in improving outcomes in adults with type 2
diabetes.
Methods: StAR2D was a 12-month two-arm randomised trial of SMS-text messaging and usual care in Cape Town,
South Africa and Lilongwe, Malawi. Messages used behaviour change theory and were developed with patients
and staff. The intervention group received four messages each week. The primary outcome was change in HbA1c.
Secondary outcomes were the proportion of patients who collected > 80% medication and changes in systolic
blood pressure, lipids, cardiovascular risk, and the proportion of the participants reaching treatment goals.
Results: The trial took place between 1 October, 2016 and 1 October 2018, 1186 participants were randomised to
intervention (593) and control (593) groups. 91% of participants completed follow-up. There was a reduction in
HbA1c (DCCT) in both groups but not in mean change (95% CI) between groups (− 0.08% (− 0.31 to 0.16) (IFCC −
0.82 mmol/mol (− 3.44 to 1.79). There was a small but not significant increase in the proportions of participants
likely to have collected 80% or more of medication (Relative risk 1.11 (0.84 to 1.47; P = 0.47). There was a significant
difference between groups in change in systolic blood pressure from baseline of 3.46 mmHg (1.48 to 5.44, P =
0.001) in favour of the intervention group. The between group difference in change in 10-year risk of coronary
heart disease was − 0.71% (− 1.46 to 0.04, P = 0.064). The proportion of participants meeting treatment goals in the
intervention group was 36.0% and in the control group 26.8% (Relative risk 1.36 (1.13 to 1.63, P = 0.001). Participants
reported many challenges to adherence despite finding messages acceptable and useful.
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Conclusions: Whilst SMS text messages do not lead to improved glycaemia in these low-resource settings there
appeared to be an impact on blood pressure and achievement of treatment goals but the mechanisms for this are
unclear. Text messages alone, may be unsuccessful unless accompanied by health system strengthening and other
forms of self-management support for type 2 diabetes.
Trial registration: Trial registration: ISRCTN, ISRCTN70768808. Registered 1 July 2015, http://www.isrctn.com/I ISRC
TN70768808.
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Background
The increasing burden of type 2 diabetes and its associ-
ated poor health outcomes disproportionately affects
populations in low- and middle-income countries
(LMIC) [1–3]. Effective management for people with
diabetes requires a system of care to be in place that in-
cludes availability of various health care providers, access
to treatments for blood glucose control as well as con-
trol of blood pressure and cholesterol levels, support for
self-management, and strategies to detect and manage
known complications from this progressive chronic con-
dition [4].
The difficulties for patients in not collecting or tak-
ing medications have been extensively described and
include a range of concerns and anxieties, lack of so-
cial support, limited health literacy, and negative in-
teractions with the health care systems and lack of
support for self-management [5, 6]. However, even
with well- systems of care in place, failure to take
medicine as prescribed or to follow other recommen-
dations around diet and lifestyle, often referred to as
nonadherence, can result in a failure to deliver the
benefits of effective medical treatments into better
outcomes for individual patients [6, 7].
Some but not all, interventions delivered by short mes-
sage service (SMS) text messaging have been effective in
increasing adherence to treatment and improving health
outcomes for a range of chronic health conditions [8–10].
A systematic review suggests significant benefits of SMS
text messaging for medication support in type 2 diabetes,
but identified substantial heterogeneity in study length,
study design with respect to the intervention and the com-
parator, and in content of the intervention. Studies in-
cluded both high- and low-income settings, however there
are few controlled studies from sub-Saharan Africa [11],
and no studies comparing interventions across different
health systems [12]. Controlled studies of longer duration,
the use of structured message development, and carried
out in sub-Saharan Africa are needed to understand and
guide the use of digital health interventions.
Following formative work to develop messages and re-
fine message delivery, we tested the effectiveness of
sending SMS text messages in improving health
outcomes and medication adherence in patients with
type 2 diabetes compared to usual care in two low- and
middle-income countries, Malawi and South Africa. We
also carried out a process evaluation using qualitative re-
search methods alongside the trial to investigate partici-
pant responses and acceptability, and we examined the
cost of the intervention through a formal cost analysis.
Methods
Study design and participants
The SMS-Text Adherence Support for Type 2 Diabetes
(StAR2D) trial was a 12-month, two parallel-arm, indi-
vidually randomised controlled trial done in two urban
sites serving patients living in middle- and low-income
settings in Southern Africa: Cape Town, South Africa, and
Lilongwe, Malawi. In Cape Town, recruitment was from a
large primary care clinic serving two low-income commu-
nities to the north of the city. In Lilongwe, where many of
the population live in low-income informal settlements,
recruitment was from a hospital-based outpatient clinic.
Despite the difference in gross domestic product between
South Africa (6374 USD) and Malawi (371 USD), in both
settings, there is an aspiration for patients to receive
health care free of charge alongside supply of a limited
range of essential medicines at no cost to patients. These
medications include those to reduce blood glucose and
blood pressure. In both sites group diabetes education ses-
sions are provided whilst attending clinics.
Randomisation and masking
We used a remote Web-based randomisation program,
Sortition (Oxford), minimising for time since diagnosis
(< 7 or ≥ 7 years), age (< 55 or ≥ 55 years), gender, and
trial site. Adults with type 2 diabetes were allocated in a
1:1 ratio to receive automated text message support plus
usual care or to usual care supplemented by active con-
trol. Allocations were directly uploaded into the trial
database to avoid creation of locally held records. Ran-
domisation was carried out remotely and independently
of the clinic and local research staff. No arrangements
for unblinding during the trial were made. We asked
participants not to share the content of their text
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messages and did not recruit more than one participant
from the same household. Clinic staff did not have ac-
cess to information about allocated groups and did not
have the facility to send text messages to individuals
through the study system. Study procedures were carried
out by trained research staff blinded to participant allo-
cation group. Medication dispensing data were collected
blind to participant allocation. Study outcomes were
assessed by laboratory staff with no knowledge of treat-
ment allocation or by research staff trained not to ask
questions that would elicit group allocation.
Intervention
The intervention was automated and consisted of motiv-
ational and educational text-messages sent to participants on
different days, three to four times weekly over a period of 12
months. The intervention development process was intended
to ensure the final brief (SMS) text-message intervention was
theory- and evidence-informed, relevant, and acceptable to
the target audiences, and appropriately aligned with the or-
ganisation of clinic care at the trial sites. Message content
was intended to encourage people to take their medicine
regularly as prescribed (70% of the messages), alongside other
information intended to provide advice about healthy lifestyle
and enhancing well-being (30% of the messages). Specific
messages encouraged people to check the date of their next
appointment and whether they had sufficient medication.
Message content was developed from lived experience of dia-
betes, diabetes treatment services and expert opinion and
formulated as SMS text-messages. The message development
was guided by the Capability, Opportunity, Motivation-
Behaviour model and described in detail a separate publica-
tion [13, 14]. Messages were translated into Xhosa, Afrikaans,
Chichewa and English. Examples of messages used are given
in supplementary appendix Table 1. Messages were ran-
domly selected from a library, using rules that ensured indi-
vidual messages were not repeated. Messages were
personalised by using information given about smoking and
use of alcohol to determine whether these messages were
sent. Messages were tailored by having participants select the
language in which to receive messages, and days on which
they did not wish to receive messages. The messaging system
allowed participants to change the delivery time or language
of messages.
Participants allocated to the usual care group were
sent a research related message thanking them for taking
part in the study and providing trial related information
every 6 weeks.
Procedures
Both groups received a message welcoming them to the
trial; instructions on how to change the phone number
to receive messages and how to withdraw from the
study, a security reminder that we would never ask for
banking or personal information, a “happy birthday”
message, and reminders to attend end of study visits. At
both study sites, routine clinical care consisted of attend-
ance to collect medication supplies at regular intervals.
Routine review appointments were recommended bian-
nually in Cape Town and annually in Lilongwe and in-
cluded screening for complications associated with type
2 diabetes carried out according to the clinical guidelines
in place at the clinic sites. Health material on type 2 dia-
betes was available at all sites, and included information
about the importance of taking medicine regularly,
alongside other health information.
Eligible patients attending clinics at both sites were those
with type 2 diabetes; aged 18 years or greater; taking an oral
glucose-lowering medication; able to communicate in one of
the predominant official languages spoken in the Western
Cape province in South Africa (English, Afrikaans, or isiX-
hosa) and in Malawi (English or the Chichewa language);
with access to a mobile phone, where shared access is
allowed with permission of the phone owner; ability to send
and receive, or be helped to send and receive text messages;
and current and planned future residence in participating
clinic communities. Patients were not eligible for recruitment
if they had been admitted to hospital for hyperglycaemia or
hypoglycaemia within the previous 3months; were pregnant
or within 3months postpartum by self-report or with plans
to become pregnant in the next 12months; had been diag-
nosed with a terminal medical condition; lived with another
member of the household already recruited to the trial; or
had participated in formative work.
Potential trial participants were approached sequen-
tially by research staff whilst attending scheduled dia-
betes care sessions at the clinics. They received verbal
and written information about the trial in their preferred
language and had the opportunity to speak to trained
study research staff and ask them questions. Initially, all
participants provided verbal assent to screening proce-
dures on agreeing to participate. If eligible, they then all
provided written consent for enrolment in the trial. Cop-
ies of the consent forms were given to participants and
randomisation was not carried out until they confirmed
they had received a “welcome” text message.
Trial data collection was carried out using a low-cost
mobile phone for data transmission. The phone ran a se-
cure implementation of Sana Mobile (MIT). The Sana
Mobile system used secure information exchange proto-
cols to link to a secure server running Open Medical Re-
cords System (OpenMRS.org). The use of this system
allowed checking of errors in data entry in real-time and
enabled data to be immediately uploaded to the trial
server.
Participants were invited by SMS text-message to at-
tend the 12-month final trial assessment which was
planned to coincide with their routine health care
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review. Participants who did not attend the 12-month
follow-up clinic appointment were followed up using the
mobile phone and other contact details. If the cause of
nonattendance was death, then hospital records were ob-
tained for review.
Data were collected by a team of research assistants
trained and supervised to ensure consistency between
and within study sites with standard operating proce-
dures for clinical measurement. Data collection took
place in clinics, community centres, and in participants
homes. Access to end of study data was restricted to
data management staff and trial statisticians.
The process evaluation will be reported in detail else-
where. Briefly, we collected data at both sites using semi
structured interviews and focus groups. We used pur-
posive sampling to explore variation in response by vari-
ables, including age, gender, and language group of
patient participants. We also developed interview guides
to explore participant experience and views of receiving
SMS text messages doing interviews at baseline (baseline
interview guide in supplementary file 2), after enrolment
and before a participant is randomised, and in interviews
and focus groups with the same group of participants at
the end of the trial (final interview guide in supplemen-
tary file 3). Trained qualitative researchers conducted
the in-depth interviews and focus groups; data was cap-
tured with field notes and digital voice recording and
was transcribed with anonymisation. Notes and tran-
scripts were coded and themes developed. Standard ap-
proaches to ensuring the quality of the methodology
were used, including dual review of interview summar-
ies, use of a coding framework, and assessment of sam-
ples of dual-coded data.
Deviations from protocol
Some participants taking insulin but not an oral glucose
lowering medication were inadvertently recruited and ran-
domised. These individuals were excluded from the ana-
lysis. The planned collection of data and notification of
participants where medication was out of stock and track-
ing of participant attendance to collect medication were
not implemented as planned. It emerged during the trial
that procedures for dispensing and tracking medication
identified in the formative work were no longer being
used. We therefore adapted the original planned message
to send as a prompt around the time a participant was cal-
culated to require a medication refill, to check the status
of their clinic appointment/medication refill. To stream-
line follow up we made the decision not to record self-
reported diet and physical activity measures at follow up.
Outcomes
We pre-specified change in HbA1c from baseline to 1
year as the primary outcome. Secondary outcomes were
the proportion of patients collecting 80% or more of
their agreed-upon, diabetes-related medication derived
from routine clinic data [15]; change in systolic blood
pressure; change in lipids; a combined measure of car-
diovascular risk based on HbA1c, lipids, and systolic
blood pressure [16]; and the proportion of the partici-
pants reaching treatment goals (HbA1c ≤8% and systolic
blood pressure < 140 mmHg).
The EuroQol 5-Dimension 3-Level (EQ-5D-3L) instru-
ment [17], and a locally adapted questionnaire, to establish
satisfaction with treatment and delivery of treatment [18,
19], were used and available in all of the study languages.
In addition, self-reported medication-taking was recorded
[20]. Basic demographic data collected included age, gen-
der, language preference, and work status. Anthropomet-
ric measures were collected, including measurement of
height and weight using standard procedures. Full specifi-
cation of secondary outcomes and methods of assessment
have been previously published [21].
Outcomes of the process evaluation aimed to deter-
mine the factors (including individual, health system and
broader contextual factors) influencing the impact of the
intervention. Detailed economic findings will be reported
in a separate paper.
Sample size calculations
We estimated that a target sample of 1066 adults (in-
cluding a loss to follow up of 20% and potential cluster-
ing between sites) would provide 90% power at 5% level
of significance (2-sided) to show a reduction of 0.5%
(5.5 mmol/mol) in HbA1c, assuming a standard devi-
ation of 2.2% (24 mmol/mol).
Statistical analysis
The study results are reported in accordance with the
Consolidated Standards of Reporting Trials (CONSORT)
2010 statements [22]. A full detailed statistical analysis
plan was prepared and finalised before participant
follow-up was completed.
The results from the trial are presented as comparative
summary statistics with 95% confidence intervals. All the
tests were done at a 5%, two-sided significance level.
Analysis of intervention effect was carried out on all par-
ticipants with non-missing outcome data and partici-
pants were analysed in the groups to which they were
allocated, regardless of what they actually received, but
those randomised but recruited in error, who were not
using an oral glucose lowering medication were
excluded.
Comparison of change in HbA1c from baseline to 1
year between the intervention and usual care groups
used a linear regression model, adjusting for baseline
HbA1c and minimising variables. The treatment effect
was presented as the adjusted difference between groups
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in the change in HbA1c from baseline, along with a 95%
confidence interval and P-value derived from the corre-
sponding t-statistic. Similar methods were used to ana-
lyse blood pressure data and other continuous
outcomes.
We estimated the proportion of scheduled medication
collection appointments successfully completed, in the
following way, using routine registers maintained in the
clinics. In Cape Town, data were obtained from two
sources: (i) record sheets for centrally dispensed medica-
tion, delivered to clinics to be picked up by participants
were used where marked to indicate collection; (ii) med-
ical records were endorsed where prescriptions were lo-
cally dispensed with the participant in attendance. In
Lilongwe, the data on participants attending were pro-
spectively collected from clinic records. Records of
duration of medication given were not available consist-
ently, we therefore used a conservative estimate of medi-
cation being dispensed at three-monthly intervals. We
then estimated, for each participant, the proportion of
required medication likely to be available over 1 year
from the attendance data. The proportions of partici-
pants who collected medication on at least 80% of
scheduled occasions were compared using a log-
binomial regression model adjusted for minimising vari-
ables. The intervention effect was presented as a relative
risk with 95% confidence interval and P-value derived
from the corresponding Z-statistic.
Missing data were reported with reasons given where avail-
able and the missing data pattern and mechanism were ex-
plored. We also did a sensitivity analysis using multiple
imputation to examine the robustness of the results.
We did pre-specified subgroup analyses of the primary
outcome and adherence outcome for the following sub-
groups: age (< 55 years or ≥ 55 years); site (Cape Town or
Lilongwe); gender (male or female); number of years with
type 2 diabetes (< 7 years or ≥ 7 years); presence of one or
more comorbidity (none, one or more); diabetes control at
baseline (HbA1c ≤53mmol/mol or > 53mmol/mol); and
self-reported adherence rating score at baseline (25 or <
25). All statistical analyses were done using Stata version
15.1 (StataCorp LLC, College Station, USA).
Laboratory measurement
HbA1c was measured using International Federation of
Clinical Chemistry calibrated analysers linked to an
international quality assurance scheme at both sites.
Total and high-density lipoprotein (HDL) cholesterol
was analysed using an enzymatic colorimetric method,
again with an international quality assurance scheme.
Data management
Electronic data capture was done with Sana mobile
(MIT) using low-cost Android mobile phones and a
real-time, mobile Internet connection to a server where
the data was stored using OpenMRS [21].
Approvals
The trial received ethical approval from the University
of Oxford Tropical Research Ethics Committee (22-15),
the University of Cape Town Human Research Ethics
Committee (126/2015) and the Malawi National Health
Services Research Committee (15/7/1425). All partici-
pants provided informed consent. The trial protocol has
been previously published [21].
Data collection, management and analytical proce-
dures were monitored by an independent data monitor-
ing committee. Trial management was also reviewed by
an independent trial steering committee.
Results
Trial recruitment began in September 2016 and follow
up of participants finished in October 2018. Of the 1930
potential participants screened, 744 were found to be
ineligible.
In total, 1186 participants were randomly allocated to
intervention (593) and control (593) (Fig. 1). There were
67 participants recruited who were subsequently identi-
fied as ineligible through using insulin alone without an
oral glucose lowering drug and these were excluded.
Baseline data were collected from all participants with
the exception that 21 participants (for example, those in
wheelchairs), could not have their weight measured with
the measuring devices available.
Baseline characteristics were similar between allocated
study groups (Table 1). Mean (SD) age was 57.1 (11.4)
years, Body Mass Index 30.7 (7.0) kg/m2, years in school
9.0 (4.0), HbA1c 10.2 (3.5) %, systolic blood pressure
131.2 (20.4) mmHg, total cholesterol to HDL cholesterol
ratio 4.4 (1.6). Of participants, 782 were women (69.9%)
and 568 (50.8%) were based in Cape Town and 551
(49.2%) based in Lilongwe. The median (Q1, Q3) dur-
ation of diabetes was 5.0 (2.8, 10.0) years, and 10-year
risk of coronary heart disease was 9.4 (4.7, 19.3) %. Mean
baseline HbA1c differed between sites. The mean (SD)
HbA1c for Cape Town was 9.1 (2.3) and for Lilongwe
11.3 (4.0)%.
The primary outcome was measured in 510 (91.4%) of
those in the intervention group and 512 (91.3%) of those in
the control group. Follow up was similar across both sites.
Exposure to the intervention was high, with a high
overall rate of delivery of SMS text messages. Out of a
total of 114,207 SMS messages, only 7644 (6.7%) were
not sent from the server or not delivered.
The HbA1c fell in both the intervention and usual care
groups, and there was no difference in the change in
HbA1c between intervention and usual care groups. The
change (reduction) in HbA1c (SD) DCCT [IFCC] from
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baseline to 1 year was − 1.15 (2.81) % [− 12.53 (30.72)
mmol/mol] in the intervention group and − 1.19 (2.86)
[− 13.02 (31.27) mmol/mol] in the control group (Fig. 2).
The overall adjusted difference in HbA1c (95% CI) be-
tween groups was − 0.08% (− 0.31 to 0.16) [− 0.82 (− 3.44
to 1.79) P = 0.537] in favour of the intervention group.
We observed no differences in medication use over time
between groups (supplementary tables).
There was a reduction in systolic blood pressure of
0.17 mmHg in the intervention group and a rise of
3.11 mmHg in the control group, with a between
group difference of − 3.46 mmHg (− 5.44 to − 1.48,
P = 0.001) in favour of the intervention group
(Table 2). We observed no differences in medication
use over time between groups (supplementary tables).
The corresponding difference in change in 10-year
risk of coronary heart disease was − 0.71% (− 1.46 to
0.04, P = 0.064). The proportion of participants meet-
ing treatment goals at one-year in the intervention
group was 36.0% and in the control group 26.8%
(Relative risk 1.36 (1.13 to 1.63, P = 0.001). There
were no other clinically important between group dif-
ferences in the clinical, self-report measures of medi-
cation use and satisfaction.
Fig. 1 Heading: Trial Profile
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Female 390 (69.9) 392 (69.9) 782 (69.9)
Male 168 (30.1) 169 (30.1) 337 (30.1)
aAge (years), n(%)
< 55 years 229 (41.0) 236 (42.1) 465 (41.6)
≥ 55 years 328 (58.8) 324 (57.8) 652 (58.3)
Missing 1 (0.2) 1 (0.2) 2 (0.2)
Age (years)
Mean (SD) 56.8 (11.6) 57.4 (11.1) 57.1 (11.4)
Range 24.8 to 97.0 28.7 to 89.6 24.8 to 97.0
Missing 1 1 2
Site, n(%)
Cape Town, SA 276 (49.5) 292 (52.1) 568 (50.8)
Lilongwe, Malawi 282 (50.5) 269 (48.0) 551 (49.2)
aDuration of diabetes (years), n(%)
< 7 years 333 (59.7) 332 (59.2) 665 (59.4)
≥ 7 years 224 (40.1) 228 (40.6) 452 (40.4)
Missing 1 (0.2) 1 (0.2) 2 (0.2)
Duration of diabetes (years)
Median 5.0 5.2 5
IQR 2.5 to 10 3 to 10.0 2.8 to 10
Missing 1 1 2
Years in school/education
Mean (SD) 9.0 (3.9) 9.1 (4.2) 9,0 (4.0)
Missing 1 1 2
Currently smoke, n(%)
Yes 68 (12.2) 72 (12.8) 140 (12.5)
No 489 (87.6) 488 (87.0) 977 (87.3)
Missing 1 (0.2) 1 (0.2) 2 (0.2)
Currently use smokeless tobacco, n(%)
Yes 22 (3.9) 21 (3.7) 43 (3.8)
No 535 (95.9) 539 (96.1) 1074 (96.0)
Missing 1 (0.2) 1 (0.2) 2 (0.2)
Tobacco Frequency, n(%)
Less than once a week 546 (97.9) 544 (97.0) 1090 (97.4)
Twice a week 0 2 (0.4) 2 (0.2)
3 to 5 times a week 0 2 (0.4) 2 (0.2)
Every or almost every day 7 (1.3) 9 (1.6) 16 (1.4)
More than once a day 4 (0.7) 3 (0.5) 7 (0.6)
Missing 1 (0.2) 1 (0.2) 2 (0.2)
Live with a smoker, n(%)
Yes 157 (28.1) 154 (27.5) 311 (27.8)
No 399 (71.5) 402 (71.7) 801 (71.2)
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Unsure 1 (0.2) 4 (0.7) 5 (0.5)
Missing 1 (0.2) 1 (0.2) 2 (0.2)
BP (mmHg)
Systolic, Mean (SD) 130.6 (20.4) 131.7 (20.4) 131.2 (20.4)
Diastolic, Mean (SD) 78.3 (10.9) 79.0 (11.4) 78.7 (11.1)
Missing 1 2 3
BMI (kg/m2)
Mean (SD) 30.6 (6.5) 30.8 (7.4) 30.7 (7.0)
Missing 8 12 20
HbA1c (%)
Mean (SD) 10.1 (3.4) 10.2 (3.6) 10.2 (3.5)
Missing 1 3 4
HbA1c (mmol/mol)
Mean (SD) 87.1 (36.8) 88.4 (38.9) 87.7 (37.8)
Missing 1 3 4
HDL Cholesterol (mmol/l)
Mean (SD) 1.2 (0.4) 1.2 (0.3) 1.2 (0.3)
Missing 1 2 3
Total Cholesterol (mmol/l)
Mean (SD) 4.9 (1.3) 4.9 (1.3) 4.9 (1.3)
Missing 4 4 8
Ratio of HDL to Total Cholesterol
Mean (SD) 0.25 (0.09) 0.25 (0.08) 0.25 (0.08)
Missing 4 4 8
SMS Language, n(%)
Chichewa 252 (45.2) 246 (43.9) 498 (44.5)
Isixhosa 109 (19.5) 108 (19.3) 217 (19.4)
English 112 (20.1) 120 (21.4) 232 (20.7)
Afrikaans 84 (15.1) 86 (15.3) 170 (15.2)
Missing 1 (0.18) 1 (0.18) 2 (0.18)
Current health, n(%)
Poor 44 (7.9) 52 (9.3) 96 (8.6)
Fair 163 (29.2) 172 (30.7) 335 (29.9)
Good 303 (54.3) 291 (51.9) 594 (53.1)
Excellent 47 (8.4) 45 (8.0) 92 (8.2)
Missing 1 (0.18) 1 (0.18) 2 (0.18)
Medication use, n(%)
Insulin 91 (16.3) 102 (18.2) 193 (17.3)
Statin 216 (38.7) 243 (43.3) 459 (41.0)
Metformin 527 (94.4) 528 (94.1) 1055 (94.3)
Sulfonylurea 396 (71.0) 378 (67.4) 774 (69.2)
Pioglitazone 0 0 0
BP lowering medication 394 (70.6) 416 (74.2) 810 (72.4)
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Missing 1 (0.18) 1 (0.18) 2 (0.18)
MARS-5b
Mean (SD) 22.7 (2.6) 22.7 (2.8) 22.7 (2.7)
Missing 1 1 2
EQ5D-3 L Index Value
Mean (SD) 0.78 (0.26) 0.78 (0.27) 0.78 (0.26)
Missing 1 1 2
Satisfaction with health care
Mean (SD) 4.2 (0.8) 4.2 (0.8) 4.2 (0.8)
Missing 1 1 2
Self-reported eating
Mean (SD) 11.8 (4.9) 11.4 (5.0) 11.6 (4.9)
Missing 1 1 2
Self-reported physical activity
Mean (SD) 7.4 (6.0) 6.7 (5.8) 7.0 (5.9)
Missing 1 1 2
10-year coronary heart disease risk (%)
Median 9.1 9.6 9.4
IQR 4.4 to 19.4 4.8 to 19.3 4.7 to 19.3
Missing 4 6 10
Number of glucose lowering medications prescribed
Mean (SD) 1.8 (0.5) 1.8 (0.5) 1.8 (0.5)
Median (IQR) 2 (2 to 2) 2 (1 to 2) 2 (2 to 2)
Missing 1 2 3
Number of blood pressure lowering medications prescribed
Mean (SD) 1.5 (1.2) 1.5 (1.2) 1.5 (1.2)
Median (IQR) 2 (0 to 2) 2 (0 to 2) 2 (0 to 2)
Missing 1 2 3
Number of cholesterol lowering medications prescribed
Mean (SD) 0.4 (0.5) 0.4 (0.5) 0.4 (0.5)
Median (IQR) 0 (0 to 1) 0 (0 to 1) 0 (0 to 1)
Missing 1 2 3
Comorbidities, n(%)
Heart attack 36 (6.5) 28 (5.0) 64 (5.7)
Heart failure 28 (5.0) 20 (3.4) 48 (4.3)
TIA/mini stroke 45 (8.1) 41 (7.3) 86 (7.7)
Angina/chest pain 50 (9.0) 41 (7.3) 91 (8.1)
Peripheral vascular disease 79 (14.2) 65 (11.6) 144 (12.9)
Chronic kidney disease 21 (3.8) 18 (3.2) 39 (3.5)
TB 47 (8.4) 58 (10.3) 105 (9.4)
Mental Illness 25 (4.5) 29 (5.2) 54 (4.8)
aVariables used in minimisation
bMedication adherence report scale
Farmer et al. BMC Public Health         (2021) 21:1907 Page 9 of 14
There was no evidence of impact on the secondary
outcome of medication adherence. Our pre-specified
cut-off for adherence of attending at least 80% of sched-
uled medication collection appointments was met by
only 15.7% of the intervention group and 14.2% of the
control group (Relative risk 1.11 (0.84 to 1.47; P = 0.47).
In addition, we carried out an exploratory analysis of ad-
herence using continuous data. This did not change the
conclusion with a mean (SD) percentage of the propor-
tion of diabetes-related medication collected over 1 year
of 56.7 (23.0)% for the intervention group and 54.2
(23.0)% for usual care (P = 0.061).
The pre-specified subgroup analyses (Table 3 and
Fig. 2) for HbA1c outcomes suggests an interaction be-
tween change in HbA1c for those with a HbA1c > 53
mmol/mol and ≤ 53mmol/mol. There is a difference be-
tween intervention and control of HbA1c (DCCT) in
favour of intervention of − 1.85 mmol/mol for HbA1c >
53mmol/mol and a difference of 0.4 mmol/mol in
favour of control for ≤53 mmol/mol (P-value interaction
< 0.0001). There was a marginal interaction for change
in HbA1c by duration of diabetes (P = 0.05). There was
no evidence of interactions for diabetes control, by site,
age, gender, or presence of comorbidities. There were 19
Fig. 2 Treatment effect on primary outcome (HbA1c mmol/mol) and treatment effect on primary outcome by subgroup
Table 2 Treatment effect on secondary outcomes
Outcomes
Change from baseline to 12months
Intervention Control Mean difference P
Systolic blood pressure − 0.17 (18.9) 3.11 (19.24) −3.46 (− 5.44 to − 1.48) 0.001
Total/HDL cholesterol −0.03 (1.3) 0.01 (1.1) −0.03 (− 0.17 to 0.10) 0.633
Body mass index (kg/m2) 0.03 (2.14) −0.07 (3.76) −0.08 (− 0.45 to 0.29) 0.669
Modelled cardiovascular risk −1.24 (8.22) −0.38 (7.94) − 0.71 (− 1.46 to 0.041) 0.064
Health status EQ-5D 0.009 (0.160) −0.004 (0.157) − 0.011 (− 0.007 to 0.030) 0.202
Medication taking (MARS) 0.6 (2.81) 0.37 (3.18) −0.26 (− 0.03 to 0.54) 0.075
Satisfaction with health care 0.27 (0.74) 0.21 (0.74) −0.030 (− 0.038 to 0.099) 0.385
Intervention Control Relative Risk (95% CI) P
Reaching treatment goals 182 (36.0) 136 (26.8) 1.36 (1.13 to 1.63) 0.001
≥80% visits for medication collection 87 (15.7) 79 (14.2) 1.11 (0.84 to 1.47) 0.469
Data on self-reported dietary intake and physical activity was not recorded at follow up
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(3.4%) deaths in the intervention group and 16 (2.9%)
deaths in the control group. There were no adverse
events related to the trial intervention.
Process evaluation
Details of our qualitative findings will be reported else-
where. In summary, participants in the intervention arm
of the trial found brief text messaging for diabetes ad-
herence acceptable and useful for addressing informa-
tional and support needs. There were some examples of
positive behaviour change reported due to the text re-
minders and advice on healthy lifestyle. There was a
strong relational effect with messages and trial partici-
pation being experienced as a source of support, car-
ing and motivation. However, participants’ ability to
act on the messages was limited, against a back-
ground of navigating a complex set of challenges in
coping with their diabetes and other life challenges.
Impact and participant responses were similar across
sites, despite socio-economic and health service differ-
ences. Common themes were participants’ frustration
over how unstable their health was, their struggle to
control their blood glucose levels, and their need for
more responsive health care.
Costs
The annualised economic cost of the study intervention
amounted to $7883 in the Malawi clinic and $6336 in
the South African clinic. Fixed costs (formative research,
set-up, and programming) represented respectively 72
and 83% of these costs. This difference is largely ex-
plained by the fact that the cost of SMS text-messages in
Malawi is twice the cost of SMS in South-Africa. If the
intervention was scaled-up and rolled out to 90% of
adults with diabetes on treatment in each country, the
shares of fixed costs decrease very significantly to 1.33%
in Malawi and 0.04% in South-Africa, the largest cost be-
coming that of the SMS text-messages. The annualised
cost of the intervention per diabetes patient year would
amount to $6.47 in Malawi and $3.16 in South-Africa.
The cost per patient year of routine treatment is $58.58
and $189.96 respectively. Including the intervention as
part of routine treatment would thus increase the cost
per patient year by 11.05% in Malawi and 1.66% in South
Africa. Costs to patients affect adherence. For patients
using private and public transport, (95% in Lilongwe and
42% in Cape Town) transport cost per visit was the
equivalent of 5 loaves of bread in Lilongwe and 2.5 in
Cape Town. Time in clinic was significant, mainly due
to waiting time. It was an average of 2.5 h in Lilongwe
and just under 5 h in Cape Town.
Discussion
The StAR2D trial does not provide convincing evidence
that well-designed text messages lead to changes in gly-
caemic control across the range of baseline HbA1c for
people with type 2 diabetes and across two low resource
settings in urban sub Saharan Africa, but there is
Table 3 Treatment effect on primary outcome and treatment effect on primary outcome by subgroup
Change in HbA1c (mmol/mol) from baseline to 12months
Interventiona Controla Mean differenceb P
HbA1c (mmol/mol) −12.5 (30.72) −13.0 (31.27) −0.82 (−3.44 to 1.79) 0.537
HbA1c at baseline
≤ 64mmol/mol 4.4 (16.39) 2.7 (15.68) 1.89 (−1.68 to 5.46) < 0.0001
> 64 mmol/mol −20.3 (32.59) − 19.7 (33.76) −2.36 (−5.70 to 0.97)
Age
< 55 years −13.7 (30.29) −15.8 (36.32) −0.28 (−4.70 to 4.14) 0.767
≥ 55 years −11.7 (31.05) − 11.0 (26.90) −1.30 (− 4.50 to 1.90)
Gender
Male −16.1 (31.88) −15.3 (33.96) −3.47 (−8.61 to 1.67) 0.248
Female − 11.1 (30.18) −12.1 (30.17) 0.17 (−2.88 to 3.22)
Duration of diabetes
< 7 years −12.8 (29.48) −14.4 (31.86) − 1.20 (−4.62 to 2.22) 0.050
≥ 7 years − 12.2 (32.53) −11.0 (30.37) −0.37 (− 4.42 to 3.68)
Self-reported medication adherence at baseline
MARS < 25 −11.5 (31.18) − 10.7 (30.74) − 1.51 (− 4.86 to 1.84) 0.258
MARS = 25 −14.4 (29.85) − 16.6 (31.83) 0.05 (− 4.18 to 4.29)
aMean (SD)
bMean (95% CI)
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evidence for a significant and clinically important impact
on blood pressure and attainment of treatment goals in
this population, although the reasons for a difference in
impact on glycaemia and blood pressure are unclear.
Findings were similar between two contrasting settings.
The process evaluation suggested that the SMS messages
were seen as relevant and useful, providing examples of
behaviour change, although messages did not appear to
address the complex reasons underlying ongoing partial
adherence behaviours or the clinical need for escalating
treatment. Set-up costs per patient become minimal
when the intervention is scaled up. Then the main cost
driver is that of cost per SMS message in the country.
We compared our study to those included in at least
one of three recent meta-analyses of SMS texts to sup-
port people with diabetes [23–25]. We found most of
the studies included were small (100 participants or less)
of short duration (3 to 6 months), focused on people
with poorly controlled HbA1c levels (defined as a
HbA1c > 7%) and compared intervention to usual care,
although usual care varied across studies. There was
variation in the content and dosage of the intervention
but no obvious dose-response pattern. In most of the
studies, both intervention and control arms showed a fall
in the level of HbA1c including those studies where the
between group difference was not significant which is
consistent with our findings. It is possible that willing-
ness to take part in a trial may also be associated with
changes in motivation relating to medication use and
other lifestyle behaviours. Larger studies and those car-
ried out over a longer period did not identify statistically
significant differences in measures of HbA1c between
intervention and control groups [23–25], with one
widely reported exception [26]. This nine-month New
Zealand study differed from ours, in that the participants
were people with type 1 and type 2 diabetes, who were
using oral glucose lowering medication and insulin and
the intervention included graphical feedback of blood
glucose readings [26]. The closed-loop communication
between participants and providers in the New Zealand
study may have enhanced the impact of the intervention.
We involved clinicians in the design of the messaging
system, but not, in day to day interaction with patients
as this would not have been feasible either in our local
context or to scale more widely. We observed that this
may have reduced our agility in responding to local
context.
The trial setting is representative of outpatient clinical
care available for most people with type 2 diabetes in
LMIC. The level of HbA1c in the population was high in
both sites and despite the long duration of type 2 dia-
betes, many people were still on oral monotherapy and
had not been prescribed additional treatment. The num-
bers of people who died during the 1 year of the trial
emphasises the extent of morbidity and mortality in this
population.
Our results showed mixed effects on outcomes that
are important for people with type 2 diabetes. For ex-
ample, we observed a similar, though larger effect of the
intervention on lowering blood pressure than that re-
ported in a previous study using SMS text-messaging to
support the regular use of medication [27], but there
was no similar impact on HbA1c. Some of the messages
focussed on cardiovascular risk factors and cardiovascu-
lar disease prevention. In pre-specified sub-group ana-
lyses, we found evidence of interaction by the level of
HbA1c at the start of the trial and by the duration of
diabetes (self-reported time since diagnosis). The results
suggest that it is possible that people with higher starting
HbA1c and shorter duration of disease may have bene-
fitted more from the intervention than those with lower
baseline HbA1c or longer duration of disease. However,
the effect is small and the mean difference in HbA1c is
not non clinically relevant. These results show the lim-
ited scope for an effect from SMS text-messages on gly-
caemic control in the absence of treatment
intensification or increased levels of support.
A cost-effectiveness analysis had originally been
planned. However, findings showed no difference be-
tween intervention and control groups for the main out-
come of the study and no difference in EQ-5D
measures, so this analysis has not been done.
StAR2D tested at scale, the use of brief messages deliv-
ered by SMS text-message for improving outcomes for
people with type 2 diabetes. HbA1c and blood pressure
outcomes were collected blind to randomly allocated
group and with minimal loss to follow up. The design of
the study excluded interim HbA1c measures that may
have identified an early, but transient change in HbA1c
level (potentially at the expense of modifying the impact
of the trial interventions) in contrast to other shorter-term
studies. We did not, for similar reasons, have additional
measures in place to self-report whether messages were
read, but our formative work did not indicate this would
be a problem, we tracked whether participants were re-
ceiving messages on their mobile phones, and they re-
ported receiving and reading them in interviews after the
trial had finished. We did not measure health literacy as a
dependent variable and did not measure whether people
had the messages read to them, but most participants
interviewed in our qualitative study had basic knowledge,
although lacked personal information about what might
be needed to stabilise their blood sugar.
This trial provided a good test of the pragmatic impact
of messaging without additional support beyond usual
clinic care. As a test of efficacy, this study was limited by
wide inclusion criteria including participants with co-
morbid conditions and those with a varied degree of
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glycaemic control. The study builds on previous work
[27], with an increased frequency of sending messages
and a message library utilising a wide range of
behaviour-change techniques and an increased number
of content domains [28].
Conclusions
In this large, robust, randomised trial in two sub-
Saharan African cities, we did not find convincing evi-
dence that well-designed text messages lead to changes
in glycaemic control for people with type 2 diabetes re-
ceiving usual primary care, although there was evidence
for a clinically important impact on blood pressure and
attainment of treatment goals. Text messages alone [11],
may be unsuccessful in achieving glycaemic control un-
less accompanied by multi-modal health system
strengthening and other forms of support for self-
management. Further work is needed on what health
service and self-management components are needed in
combination with targeted digital communication using
a wider range of approaches, to support diabetes adher-
ence behaviour.
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